What dodging second apron means for Boston Celtics trade possibilities
The Celtics made a big first step in their offseason on Tuesday, dipping below the second apron threshold ($207 million) by trimming roughly $24 million from their payroll with the trades of Kristaps Porzingis and Jrue Holiday. There are many more moves to come for the Celtics this offseason, league sources tell MassLive as Boston looks to retool its roster for the future following Jayson Tatum's torn Achilles. However, Brad Stevens' prompt work of dumping money ahead of the NBA Draft now opens more doors for the franchise heading into the heart of the NBA offseason.
So what exactly does getting under the second apron do for the Celtics when it comes to future trade and free agent possibilities? Let's examine where the roster is at and the benefits it provides for future dealing.
Advertisement
CELTICS 2025-26 ROSTER
Jayson Tatum: $54.1 million
Jaylen Brown: $53.1 million
Derrick White: $28.1 million
Anfernee Simons: $27.6 million
Sam Hauser: $10 million
Georges Niang: $8.2 million
Payton Pritchard: $7.2 million
Baylor Scheierman: $2.6 million
Xavier Tillman: $2.5 million
Neemias Queta: $2.3 million
Jordan Walsh: $2.2 million (non-guaranteed)
No. 28 pick: $2.5 million
JD Davison: $2.2 million (team option)
Total: $203 million to 13 players
THINGS CELTICS CAN NOW DO BY GETTING UNDER SECOND APRON THRESHOLD
Aggregate (combine) salaries in a trade: This is a simple but significant tool. Before, Boston could only send out one player at a time in a trade. Now, Boston can ship out multiple players in a deal simultaneously.
Advertisement
Send out cash in a trade: NBA teams are permitted to send up to $7.2 million in a trade during a season if they are below the second apron. This can become a valuable sweetener to convince a team to take on an unwanted contract. The Celtics did not have access to use this money at all in trades last season. Now, it's a weapon at their disposal again for deals in 2025.
Access to 2033 first-round pick to trade: The Celtics will have to wait a couple of years (and stay under the second apron) to have access to trade their 2032 first-round pick after staying above the second apron last year. However, their 2033 first round pick has been unfrozen by dipping under the second apron now.
RESTRICTIONS CELTICS STILL FACE WHILE ABOVE FIRST APRON ($195 MILLION)
Access to smaller taxpayer mid-level exception ($5.7 million): The Celtics' usage of this MLE would trigger a hard cap at the second apron ($207 million). Given where Boston is with their repeater tax penalties, it would be surprising to see Boston use the MLE this offseason since getting under the tax line entirely could be a priority.
Advertisement
Can't take back more than 100 percent of salary sent out in trade: This is a simple restriction that was also in place for all second apron teams. Essentially, Boston can't send out a $30 million dollar player and take back one making $31 million. The salary matching rules get much easier to manage if the Celtics drop below the first apron ($195 million), which would require trimming another $8 million in salary.
Can't use traded player exceptions (yet): The Celtics have created a pretty big TPE ($22 million) in the Kristaps Porzingis trade but don't have access to it if their payroll stays this high. That changes if they drop under the first apron.
Final thoughts
The Celtics' initial moves trimmed roughly $260 million in payroll and luxury tax penalties for the 2025-26 season. However, Boston is still facing a sizable tax bill ($68 million) with their current roster and has basketball incentives to keep trimming the payroll as well in order to open the door for more flexibility and team building tools moving forward.
Advertisement
Getting below the first apron ($195 million) is a logical next step for Boston and it would not be surprising at all to see Boston give themselves the option to get under the luxury tax threshold entirely ($187 million) for the 2025-26 season.
More Celtics content
Read the original article on MassLive.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Citi Maintains ‘Neutral' Rating on EchoStar Corporation (SATS); Raises PT
EchoStar Corporation (NASDAQ:SATS) is one of the best stocks for a . The corporate headquarters of a satellite radio systems company, illuminating the skyline. As announced on June 24, 2025, Citi maintained a 'Neutral' rating on EchoStar Corporation (NASDAQ:SATS), raising its price target from $27 to $28.50. The analyst cited its reevaluation of EchoStar's potential value related to its spectrum assets. These assets include the company's licenses for radio frequencies used for communication. Furthermore, Citi expects a strategic update to be announced by the company within 30 days. The analyst highlights its importance as this expected development would come at a critical time, as EchoStar approaches a bond-related interest payment milestone. EchoStar Corporation (NASDAQ:SATS), a U.S.-based telecommunications company, delivers broadband, wireless, and satellite services through its Pay-TV, Retail Wireless, and BSS segments, and is also part of our growth stock portfolio. While we acknowledge the potential of SATS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Overlooked Tech Stocks to Buy Now and 10 Low Risk High Reward Stocks Set to Triple by 2030. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 minutes ago
- Yahoo
BMO Capital Maintains ‘Outperform' Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a . A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. BMO Capital maintained an 'Outperform' rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company's stock from $300 to $360. BMO Capital attributed this update to a drastic increase in Amvuttra sales for ATTR-CM, according to IQVIA tracking data, after the drug's approval in March. Furthermore, the analyst cited the continued consistency of the company's sales trends, reinforcing confidence in its commercial traction. While short-term skepticism exists regarding the company's revenue growth, Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) consistent historical trend of revenue and pipeline growth supports its potential for continued growth. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company, develops and markets RNAi therapeutics for rare and genetic diseases. The company has demonstrated consistent YoY revenue growth, making it part of the growth stock portfolio. While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: 10 Best Marketing Stocks to Buy Right Now and 10 Best Cybersecurity Stocks to Invest in Under $20. Disclosure: None.
Yahoo
7 minutes ago
- Yahoo
Tigers ace Tarik Skubal strikes out 8 Twins in 3 innings, 13 total in dominant, 1-hit win
There was no need for Tarik Skubal to change things up because his changeup was working. The Tigers ace used his best off-speed pitch in a dominant 13-strikeout effort on Sunday to lead Detroit to a 3-0 win over the Minnesota Twins. Advertisement The the hard-throwing lefty fanned five of the first six Minnesota Twins faced. He got all of them swinging. That was the ninth time Skubal has collected five strikeouts through two innings of a game, twice more than any other Tigers pitcher since the mound was lowered in 1969, according to Sarah Langs. Fast forward to the top of the third inning, and the 2024 AL Cy Young Award winner struck out the side. He got second baseman Brooks Lee with a four-seam fastball. Then he went back to his changeup to punch out third baseman Jonah Bride and catcher Christian Vázquez. They went down swinging, too. Advertisement After his seventh straight K, Tigers faithful erupted in Comerica Park. The 6-foot-3, 240-pound Skubal walked off with well-deserved swagger that his 52-win team commands. For the first time in his career, Skubal had eight strikeouts through three innings. Before the next inning's end, the 28-year-old southpaw had struck out all nine batters in Minnesota's lineup. Skubal didn't allow a hit until the fifth inning. It was a single. And it was the only hit he allowed all day. He didn't allow a walk until the sixth inning. It was on a full count. Skubal had 11 strikeouts by that point, and his Tigers had a 3-0 lead, in large part thanks to right fielder Kerry Carpenter, who homered in the first and then hit an RBI triple in the fifth. Advertisement Skubal set a new single-game career high in the seventh inning with his ninth strikeout via changeup. That same frame, he upped his K total to 13, getting Twins first baseman Ty France looking on a 99 mph four-seam fastball. After that, his day was done. His final line: 7 innings pitched, 1 hit, 1 walk, 13 strikeouts, 0 runs. Skubal entered the night with a 2.29 ERA and a 9-2 record to go along with his 125 strikeouts — the fourth most in baseball — and an MLB-leading 0.87 WHIP. His ERA dropped to 2.15 after Sunday's seven shutout innings.